Logo image
Role of macrophages in the immunotherapy of Lewis lung peritoneal carcinomatosis
Journal article   Peer reviewed

Role of macrophages in the immunotherapy of Lewis lung peritoneal carcinomatosis

Paul K. Wallace and Page S. Morahan
Journal of leukocyte biology, v 56(1), pp 41-51
Jul 1994
PMID: 8027669

Abstract

adoptive immunotherapy biological response modifiers flow cytometry Lewis lung carcinoma macrophage MVE‐2
The underlying cellular mechanisms for the antitumor effects of biological response modifiers (BRMs) have not been clearly resolved. We have investigated this issue in the Lewis lung (3LL) peritoneal carcinomatosis model in which treatment with the BRM MVE‐2 slows tumor growth and enhances survival. MVE‐2 is a potent inducer of cytotoxic macrophages (mφs); however, the in vivo tumoricidal properties of these mφs remain to be firmly established. To directly establish that mφs were at least in part responsible for the in vivo efficacy of MVE‐2, a novel method of obtaining highly enriched mφ suspensions was developed which gave high purity, satisfactory yield, and excellent viability without affecting antitumor activity. Using the 3LL peritoneal carcinomatosis model and adoptive transfer techniques, we directly demonstrate that the majority of antitumor activity was associated with the adherent cell fraction enriched for mφs. Histological observations supported this conclusion, indicating that MVE‐2 treatment initially activated cells associated with nonspecific immunity, retarding tumor growth in the ascites long enough for a multifaceted immune response to develop. J. Leukoc. Biol. 56: 41–51; 1994.

Metrics

4 Record Views
14 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Cell Biology
Hematology
Immunology
Logo image